Effect and mechanisms of Yuquan capsules combined with epalrestat on treatment of type 2 diabetes patients with peripheral neuropathy
Objective To investigate the efficacy of Yuquan capsules combined with epalrestat on treating type 2 diabetes patients with peripheral neuropathy and the impact on Keap1/Nrf2/ARE pathway.Methods 163 type 2 diabetes patients with peripheral neuropathy in Shijiazhuang Hospital of Traditional Chinese Medicine from June 2021 to January 2023 were randomly divided into experimental group(82 cases)and control group(81 cases).The control group was given epalrestat tablets and the experimental group was offered Yuquan capsules on this basis,both for 6 months.Clinical efficacy,changes in nerve conduction function and expression levels of Keap1/Nrf2/ARE in serum were compared between the two groups.Results The overall response rate of the experimental group was significantly higher than that of the control group(P<0.05).The conduction velocity and amplitude of median nerve and common peroneal nerve motor nerve(sensory nerve)in the two groups were remarkably higher after the treatment than before the treatment(P<0.05),and the latency was remarkably lower(P<0.05),with the experimental group showing greater improvement than the control group(P<0.05).The relative expression level of Keap1 protein in the two groups was remarkably lower after the treatment than before the treatment(P<0.05),and the relative expression levels of NQO1,Nrf2 and ARE proteins were remarkably higher(P<0.05),with the experimental group showing greater improvement than the control group(P<0.05).There was no adverse drug reaction(ADR)in the two groups during the treatment.Conclusion Yuquan capsules combined with epalrestat had significant clinical efficacy on treating diabetes patients with peripheral neuropathy,which could considerably improve the nerve conduction function of the patients.The action mechanism might be related to the regulation of Keap1/Nrf2/ARE signal transduction pathway.
Type 2 diabetesPeripheral neuropathyYuquan capsuleEpalrestatKeap1/Nrf2/ARE pathway
万方数据
维普
